Polycythemia Vera

• FDA label_change · 2012-01-26
  FDA Approved: DROXIA — Supplemental Application (Waylis Therapeutics LLC)

  FDA approved a supplemental application for DROXIA (hydroxyurea) from Waylis Therapeutics LLC, indicating a label change/expansion. The docu…

• CLINICAL_TRIALS research · 2011-12-12
  Clinical Trial Update: A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia [Phase 2]

  This is a Phase 2 clinical trial evaluating MK-0683 for efficacy in Polycythemia Vera and Essential Thrombocythemia; current status is unkno…

• CLINICAL_TRIALS trial_result · 2011-04-05
  Clinical Trial Update: A Safety Study of XL019 in Adults With Myelofibrosis [Phase 1]

  This clinical trial update reports termination of a Phase 1 safety study of XL019 in adults with myelofibrosis and related myeloproliferativ…

• CLINICAL_TRIALS trial_result · 2010-05-17
  Clinical Trial Update: Treatment of Polycythemia Vera With Gleevec [Phase 2]

  A Phase 2 trial evaluating imatinib (Gleevec) for polycythemia vera has completed.

• FDA approval · 2006-09-19
  FDA Approved: DROXIA — Supplemental Application (Waylis Therapeutics LLC)

  FDA approves a supplemental application for DROXIA (hydroxyurea) submitted by Waylis Therapeutics LLC.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2006-08-15
  FDA Approved: HYDROXYUREA — Supplemental Application (Endo USA, Inc.)

  The FDA approved a supplemental application for HYDROXYUREA submitted by Endo USA, Inc.

• FDA approval ·
  FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

  FDA approves Mimrylo (rusfertide) as the first drug of its kind for adults with polycythemia vera, a rare blood disorder causing excess red …